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Introduction: It has been estimated that the proportion of never-
smokers among females with lung cancer is 53% worldwide and 75% 
in Korea. We conducted a two-stage study to identify genetic factors 
responsible for lung cancer susceptibility in female never-smokers.
Materials and Methods: In a discovery set, 1969 potentially functional 
single nucleotide polymorphisms (SNPs) of 1151 genes, which were 
related to cancer development and progression, were evaluated using 
the Affymetrix custom-made GeneChip in 181 female never-smokers 
with lung cancer and 179 controls. A replication study was performed 
on an independent cohort of 596 cases and 1194 healthy controls.
Results: Sixteen SNPs with p < 0.05 for genotype distribution in 
the discovery set were enrolled in the replication study. Among 16 
SNPs, three SNPs (colony-stimulating factor 1 receptor [CSF1R] 
rs10079250A>G, tumor protein p63 [TP63] rs7631358G>A, and core-
pressor interacting with RBPJ 1 [CIR1] rs13009079T>C) were found 
to be significantly associated with lung cancer in the same direction as 
the discovery set. Homology-based model for CSF1R indicated that 
the rs10079250A>G leads to increased positive charge of CSF-binding 
region of CSF1R, thereby increasing the chance of binding between 
CSF and CSF1R. In addition, this SNP was found to increase the phos-
phorylation of a mitogen-activated protein kinase, JNK.
Conclusions: Our results suggest that the three SNPs, particularly 
CSF1R rs10079250, may contribute to lung cancer susceptibility in 
never-smoking females.
Key Words: Lung cancer, Polymorphism, Never-smokers.
(J Thorac Oncol. 2014;9: 1647–1655)
Global statistics estimate that 15% of lung cancers in men and 53% in women occur in lifelong never-smokers, 
overall accounting for 25% of all lung cancers worldwide and 
30% to 40% in Asians in the Pacific Rim countries.1–3 Notably, 
the proportion of never-smokers among women with lung 
cancer is remarkably high in Asian countries, ranging from 
90% in Taiwan and 75% in Korea to 44% in Hong Kong, com-
pared with that (15%) in the United States.4,5
A meta-analysis found a 1.5-fold increase in lung can-
cer risk associated with family history of lung cancer among 
never-smokers,6 suggesting that lung cancer risk in never-
smokers may be in part genetically determined. Candidate 
gene association studies in never-smokers have been limited 
to a few studies of modest sample sizes and have focused on 
the same set of candidate genes as those evaluated in smok-
ers, including genes involved in metabolism of carcinogens in 
tobacco smoke, and DNA damage repair.7,8
A number of genome-wide association (GWA) studies, 
primarily performed in cigarette smokers, have shown that 
polymorphic variation at 5p15.33 (TERT-CLPTM1L), 6p21.33 
(BAT3-MSH5), and 15q25.1 (CHRNA5-CHRNA3) loci influ-
ences the risk of lung cancer in populations of European 
background.9–12 The replication studies conducted in never-
smokers have found that among the three loci identified in the 
GWA studies,9–12 only the 5p15.33 locus was associated with 
the risk for lung cancer.13,14 A GWA study of never-smokers 
from an American population showed that a novel genetic 
variant GPC5 rs2352028 at 13q31.3 was associated with the 
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risk of never-smoker lung cancer, although the genetic vari-
ants at 5p15.33 were not.15 However, the association between 
the GPC5 rs23522028 and the risk of never-smoker lung 
cancer also failed to be replicated in a subsequent study con-
ducted in Caucasian populations.16 Recently, a number of 
variants, including variants at 3q28 and 18p11.22 loci, have 
been shown to contribute to the risk of lung cancer among 
never-smokers in Asian populations,17,18 which should be also 
replicated in future studies with larger populations.19 There are 
some important issues limiting the value of GWA studies such 
as low reproducibility, low predictability, and unexplained 
heritability.20,21 In addition, our understanding of the biologi-
cal basis of GWA study results is incomplete because most of 
the variations identified in GWA studies are not causal.20
The carcinogenesis is a multistep process characterized 
by the accumulation of multiple genetic and epigenetic altera-
tions, which results in alterations in cell physiology that col-
lectively dictate malignant growth: self-sufficiency of growth 
signals, insensitivity to growth-inhibitory signals, evasion 
of apoptosis, limitless replicative potential, sustained angio-
genesis, and tissue invasion and metastasis.22 Although GWA 
studies have found that many genes not previously suspected 
of having a role in lung carcinogenesis affect the risk of lung 
cancer, we hypothesized that variants in the genes which were 
known to play important roles in carcinogenesis may con-
tribute to lung cancer susceptibility. In the present study, to 
identify genetic factors responsible for lung cancer suscepti-
bility in never-smoking women, we evaluated the association 
between potentially functional genetic polymorphisms in can-
cer-related genes and lung cancer risk in a Korean population 
of never-smoking women.
MATERIALS AND METHODS
Study Populations
A total of 181 female patients who were never-smokers 
and histologically confirmed with lung cancer at Kyungpook 
National University Hospital (KNUH) in Daegu, Korea, were 
included in a discovery set. Never-smokers were defined as indi-
viduals who had smoked less than 100 cigarettes during their 
lifetime. The control subjects (n = 179) were randomly selected 
from a pool of healthy volunteers who visited the general health 
check-up center at the hospital and matched with the cases for 
age. The subjects in the study were recruited from an ongoing 
lung cancer molecular epidemiologic study as described previ-
ously.23,24 This study was approved by the Institutional Review 
Board of KNUH (Approval No., KNUHBIO_09-1018), and 
written informed consent was obtained from all participants. 
Genomic DNA samples of cases and healthy controls were 
provided by the National Biobank of Korea – KNUH, which 
is supported by the Ministry of Health, Welfare and Family 
Affairs. Genomic DNA was extracted from peripheral blood 
lymphocyte using QuickGene-810 system (Fujifilm, Tokyo, 
Japan). All case and control subjects were ethnic Koreans 
residing in Daegu or the surrounding regions.
For an independent validation set, a total of 596 patients 
and 1194 control subjects were collected. One hundred ninety 
cases were obtained from KNUH, 108 from Korea University 
Anam Hospital, 189 from Seoul National University Hospital, 
and 109 from Seoul National University Bundang Hospital. 
Among the 1194 controls, genomic DNA samples from 267 
controls were provided by the National Biobank of Korea – 
KNUH, 395 by Seoul National University Hospital, 232 by 
Seoul National University Bundang Hospital, and 300 with 
matched data by the Korean Biobank Project (4851-307, 
KBP-2011-24) and the Korean Genome and Epidemiology 
study (4845-302) that were supported by the Korea Centers 
for Disease Control & Prevention, Republic of Korea. Written 
informed consent was obtained from all the subjects at each of 
the participating institutions. Research protocol was approved 
by the Institutional Review Board at each institution.
Selection of Polymorphisms and Genotyping
We selected 1784 candidate genes involved in cancer-
related pathways from the database of SABiobioscience (http://
sabiobioscinece.com) and DAVID Bioinformatics Resources 
6.7 (http://david.abcc.ncifcrf.gov). These genes are involved in 
apoptosis (n = 96), angiogenesis (n = 86), DNA damage sig-
naling and repair (n = 74), carcinogen metabolism (n = 38), 
maintenance of genome stability (n = 34), cell cycle regulation 
(n = 65), growth factor signaling (n = 69), signal transduction 
pathway (n = 67), invasion and metastasis (n = 42), and so on. 
To identify potentially functional single nucleotide polymor-
phisms (SNPs) in the selected 1784 genes, 4215 putative func-
tional SNPs were collected using the public database (http://
www.ncbi.nlm.nih.gov/ SNP) in the promoter region (~1.0 kb), 
exons (only nonsynonymous), intron–exon boundaries (20 bp 
on either side of the introns), and the 5′- and 3′-untranslated 
regions (UTRs) of the genes. Among 4215 SNPs captured, 
1969 SNPs of 1151 genes were genotyped using the Affymetrix 
custom-made GeneChip (Affymetrix Inc., Santa Clara, CA) 
because other SNPs could not be applied to the platform. The 
list of the captured SNPs and the genotyped SNPs in a dis-
covery set is shown in Supplementary Table 1 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A679).
For validation, 16 SNPs with p < 0.05 for genotype 
distribution in the discovery set were selected (Table 2) and 
genotyped using SEQUENOM’s MassARRAY iPLEX assay 
(SEQUENOM Inc., San Diego, CA) or restriction fragment 
length polymorphism assay. For quality control, the genotyp-
ing analysis was performed “blind” with respect to the case/
control status. Approximately, 5% of samples in the validation 
set were randomly selected to be genotyped again. The results 
were 100% concordance.
Construction of a Homology-Based Model for 
CSF1R Wild Type and Variant Type (H362R)
Three-dimensional models of the colony-stimulating 
factor 1 receptor (CSF1R, also known as macrophage colony-
stimulating factor receptor) were built based on the x-ray crys-
tal structure of the ectodomain of v-kit Hardy-Zuckerman 4 
feline sarcoma viral oncogene homolog (KIT) (PDB 2e9w), 
which showed 26% sequence identity. The initial model was 
created by SWISS-MODEL program (http://swissmodel.
expasy.org), which incorporates a molecular dynamics sim-
ulation to minimize the energy of backbone and side chain 
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conformations and a loop-building process. These calculations 
were performed using the default parameters. After construc-
tion, the model was examined using PROCHECK program 
(http://www.ebi.ac.uk/thornton-srv/software/PROCHECK) 
to inspect and validate protein structural properties, such as 
residue geometry and conformation.25 The models were fur-
ther built as a dimer using MODELLER program, version 
9.2 (http://www.salilab.org/modeller).26,27 The surface electro-
static potential was calculated using DelPhi calculation and 
displayed using Pymol (http://www.pymol.org). To obtain 
three-dimensional model of CSF1R variant type (R362), the 
His residue was mutated in silico to Arg without alteration of 
backbone geometry using Pymol program.
Construction of Expression Plasmids
To examine the potential effect of wild type (H362) and 
variant type (R362) of CSF1R protein on its expression, we con-
structed wild-type and variant type plasmids. The entire open 
reading frame of CSF1R was amplified using 5′-GCG AAT 
TCA ATG GGC CCA GGA GTT CTG CTG-3′ (forward) and 
5′-CCG GGA TCC CCC TGT CGT CAA CTC CTC AGC-
3′ (reverse) primers on a CSF1R clone purchased from Open 
Biosystems (Thermo Scientific, Rockford, IL). The polymerase 
chain reaction products were cloned into the EcoRI/BamHI site 
of the p3×FLAG pCMV10 vector. The variant type (R362) con-
struct was created from p3×FLAG-CSF1R-wild type (H362) 
using the Quick-change II Site-Directed Mutagenesis kit 
(Stratagene, Cedar Creek, TX) according to the manufacturer’s 
protocol. The mutagenesis experiment was amplified using 
5′-CCA AGG ACA CAT ACA GGC GCA CCT TCA CCC 
TCT CTC TGC-3′ (forward) and 5′-GCA GAG AGA GGG 
TGA AGG TGC GCC TGT ATG TGT CCT TGG-3′ (reverse) 
primers. Both constructs were verified by sequencing analysis.
Cell Culture and Transfection
The 293T cells and A549 cells were cultured separately 
in Dulbecco's Modified Eagle Medium (DMEM) and Roswell 
Park Memorial Institute (RPMI) 1640 media supplemented 
with 10% heat-inactivated fetal bovine serum. Cells were 
seeded in a six-well plate as the cells were approximately 70% 
confluent. The next day, cells were transfected with p3×FLAG-
wild type (H362), p3×FLAG-variant type (R362), or p3×FLAG 
pCMV10 empty vector using the Effectene (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol. One 
day after transfection, cells were serum starved for 24 hours 
before treatment with recombinant human macrophage col-
ony-stimulating factor (M-CSF; R&D Systems, Minneapolis, 
MN) and harvested.
Western Blot
The 293T cells and A549 cells were treated with M-CSF 
in the media for 20 minutes before the cells were harvested 
with 200 μl of RIPA lysis buffer (25 mM Tris–HCl pH 7.6, 
150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 
0.1% SDS), supplemented with protease inhibitor (Sigma, 
St. Louis, MO); 293T cells without M-CSF treatment were 
collected as controls. Western blots were prepared by stan-
dard procedures using anti-FLAG (Sigma), anti-actin (Santa 
TABLE 1.  Characteristics of the Study Population for Association Study
Variables
Discovery Validation Combined
Cases  
(n = 181)
Controls 
(n = 179) p
Cases  
(n = 596)
Controls  
(n = 1194) p
Cases  
(n = 777)
Controls  
(n = 1373) p
Age (years)
  Mean ± SD 61.7 ± 9.9 60.8 ± 9.4 0.353a 61.7 ± 11.1 57.0 ± 12.1 <0.001a 61.7 ± 10.8 57.5 ± 11.8 <0.001a
Histological types
  Squamous cell ca. 9 (5.0)b 25 (4.2) 34 (4.4)
  Adenocarcinoma 160 (88.4) 544 (91.3) 704 (90.6)
  Large cell ca. 2 (1.1)  4 (0.7)  6 (0.8)
  Small cell ca. 9 (5.0)  5 (0.8) 14 (1.8)
  NSCLC 1 (0.6) 18 (3.0) 19 (2.4)
Stage
  I 52 (28.7) 271 (50.5)c 323 (45.0)
  II 10 (5.5) 39 (7.3) 49 (6.8)
  III 42 (23.2)  97 (18.1) 139 (19.4)
  IV 77 (42.5) 130 (24.2) 207 (28.8)
EGFR mutation statusd
  Negative 19 (67.9)  93 (37.8)e 112 (40.9)
  Positive 9 (32.1) 153 (62.2) 162 (59.1)
at test.
bNumbers in parentheses indicate column percentage.
cp < 0.001.
dEGFR mutation status was available in 28 cases for discovery set and 246 cases for validation set.
ep = 0.002.
SD, standard deviation; NSCLC, non–small-cell lung cancer; ca., carcinoma.
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Cruz, CA), anti-JNK, and anti-phospho-JNK (Cell Signaling 
Technology, Beverly, MA). Immunoreactivity was detected 
by an Immunobilon Western chemiluminescence reaction 
(Millipore, Billerica, MA).
Statistical Analysis
The results for patients and control subjects were com-
pared using Student’s t tests and the χ2 test for continuous 
variables and categorical variables, respectively. The Hardy–
Weinberg equilibrium was tested by comparing observed and 
expected genotype frequencies using a χ2 test with 1 degree of 
freedom. Unconditional logistic regression analysis was used 
to calculate odds ratios and 95% confidence intervals (CIs), 
with adjustment for age as a continuous variable. All the anal-
yses were performed using Statistical Analysis Software for 
Windows, version 9.2 (SAS Institute, Gary, NC). Data calcu-
lation and statistical analysis for western blot were performed 
using GraphPad Prism 3-5.0 software (GraphPad Software, 
San Diego, CA). The statistical significance of differences 
between groups was determined with Student’s t test under 
treatment and experiment as factors. Differences were consid-
ered statistically significant at p < 0.05.
RESULTS
Associations between SNPs 
and Lung Cancer Risk
The demographics of cases and controls enrolled in the 
discovery and the validation sets are shown in Table 1. There 
were no significant differences between cases and controls 
for mean age in the discovery set, but mean age of the cases 
was significantly higher than that of the controls in the vali-
dation set. Of the cases, 88.4% (160 of 181) and 91.3% (544 
of 596) were adenocarcinomas in the discovery and the vali-
dation sets, respectively. The distribution of stage and EGFR 
mutation positive rate among lung cancer patients were sig-
nificantly different between the two sets (p < 0.001 and p = 
0.002, respectively). The difference in EGFR mutation posi-
tivity may be attributable to detection methods with different 
sensitivity among participating institutes.
From the 1969 SNPs genotyped in the discovery set, 
554 SNPs were excluded; (1) 81 SNPs of failed genotype, (2) 
123 SNPs with genotype call rate less than 90%, (3) 264 SNPs 
of minor allele frequency less than 5%, or (4) 86 SNPs show-
ing deviation from Hardy–Weinberg equilibrium (p < 0.05) in 
the controls and therefore analyzed 1415 SNPs in 929 genes 
for the association with lung cancer risk. Approximately 50% 
of the SNPs were located in promoter region, 21% in exons 
(nonsynonymous SNPs), 16% in exon–intron boundaries, 7% 
in 5′-UTRs, and 6% in 3′-UTRs.
Of the 1415 SNPs analyzed in the discovery set, 16 
SNPs with p < 0.05 for genotype distribution (Table 2) were 
enrolled in a replication study with an independent set of 596 
cases and 1194 controls. Of the 16 SNPs, three SNPs (col-
ony-stimulating factor 1 receptor [CSF1R] rs10079250A>G, 
tumor protein p63 [TP63] rs7631358G>A, and corepressor 
interacting with RBPJ 1 [CIR1] rs13009079T>C) were sig-
nificantly associated with lung cancer in the same direction 
as the discovery set in the independent validation set when 
adjusted for age (Table 3). In combined analysis, CSF1R 
rs10079250A>G and TP63 rs7631358G>A were associated 
with a significantly increased risk of lung cancer and CIR1 
rs13009079T>C with a significantly decreased risk (adjusted 
ORs [aORs] = 1.22, 95% CI = 1.07–1.40, p = 0.003; aORs 
= 1.22, 95% CI = 1.07–1.39, p = 0.002; aORs = 0.80, 95% 
CI = 0.68–0.93, p = 0.003, respectively, in codominant 
model). Using Cochran–Mantel–Haenszel analysis, we did 
not observe any heterogeneity in odd ratios between the dis-
covery and validation sets (p ≥ 0.05).
We further investigated the association between the 
three SNPs and the risk of lung cancer after stratifying the 
subjects according to age, disease stage, and EGFR mutation 
status. As shown in Supplementary Table 2 (Supplemental 
Digital Content 2, http://links.lww.com/JTO/A680), the effect 
size and direction of association for CSF1R rs10079250, 
TP63 rs7631358, and CIR1 rs13009079 were not significantly 
different according to age, stage, and EGFR mutation status 
(p for heterogeneity > 0.05, for all). Therefore, the results sug-
gest that age, stage, and EGFR mutation status have no signifi-
cant impact on the association between the SNPs and the risk 
of lung cancer in never-smoking females.
The Effect of rs10079250 (H362R) on the 
Structure and Function of CSF1R Protein
The CSF1R model (Fig. 1) was derived from the crystal 
structure of ectodomain of KIT bound to CSF1 (also known 
as M-CSF). Although CSF1R shared only 26% identity with 
the selected KIT template, a useful model of the CSF1R 
ectodomain could be created because of the strong struc-
tural conservation found between two proteins. The CSF1-
CSF1R interaction displayed by the model must be validated 
with subsequent experimental works. The His362 is facing the 
other counterpart of dimer and is placed on the upper part of 
dimerization surface. Since the modeling structure suggested 
His362 is exposed to solvent, we mutated this residue to Arg in 
silico without alteration of backbone geometry to investigate 
the functional effect of H362R. As shown in Figure 1B, His-to-
Arg change at codon 362 provides significant positive elec-
tronic surface. The CSF1-binding region of CSF1R comprises 
positively charged residues to facilitate interaction with nega-
tively charged CSF1. Although CSF1 binding is mediated by 
a distant region of the SNP site, we suggest that the additional 
positive charge of R362 might increase the chance of interac-
tion with CSF1. This result provides a hint of mechanisms for 
the association between the rs10079250G (Arg) allele and the 
increased risk of lung cancer.
The Effect of CSF1R Variant Type (R362) on the 
Activation of a Downstream Molecule, JNK
To assess the functional importance of CSF1R variant 
type (R362) identified in this study, the effect of the variant 
type (R362) on CSF1R was investigated in vitro. Flag-tagged 
wild type (H362) and variant type (R362) were transfected into 
293T cells. Upon stimulation with M-CSF, the phosphoryla-
tion of JNK in the variant type (R362) was significantly higher 
compared with that in the wild type (H362). Similarly, in the 
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absence of M-CSF stimulation, the phosphorylation of JNK 
was significantly higher in the variant type (R362) than in the 
wild type (H362) (Fig. 2). In agreement with the result from 
293T cell lines, the phosphorylation of JNK in the R362 was 
significantly higher compared with the H362 in A549 cell lines 
(Supplementary Figure 1, Supplemental Digital Content, 
http://links.lww.com/JTO/A681). These findings suggest that 
CSF1R variant type (R362) affects the phosphorylation of JNK, 
a downstream target of CSF1R.
DISCUSSION
We conducted a two-stage case–control study using 
Affymetrix custom-made GeneChip to evaluate 1415 
SNPs in 929 candidate genes potentially involved in car-
cinogenesis to identify genetic variations associated with 
lung cancer risk among female never-smokers. Three SNPs 
(CSF1R rs10079250A>G, TP63 rs7631358G>A, and CIR1 
rs13009079T>C) were convincingly replicated across both 
stages of the study. In addition, homology-based model for 
CSF1R suggests that rs10079250A>G leads to increased posi-
tive charge of CSF-binding region of CSF1R, thereby increas-
ing the chance of binding between CSF and CSF1R. These 
findings suggest that the three SNPs, particularly CSF1R 
rs10079250A>G, may influence susceptibility to lung cancer 
in never-smoking women.
CSF1 is a homodimeric growth factor that acts through 
the cell surface receptor CSF1R, a member of the class III 
receptor tyrosine kinases including KIT, FLT3, and PDGFR, 
alpha and beta.28 Activation of CSF1R by CSF1 leads to 
receptor dimerization and autophosphorylation of tyrosine 
FIGURE 1.  Homology-based model for CSF1R wild type (H362) and variant type (R362). A, The homology models of CSF1R dimer 
(colored with yellow and green) were built using the SWISS-PRO and MODELLER program (v9.2) using the complex structure of 
ectodomain of KIT (purple) and CSF1 (blue and light blue) (2e9w); (B) single nucleotide polymorphism (SNP) residue histidine is 
highlighted in yellow; (C) the surface electrostatic potential of wild type and variant type CSF1R was calculated using DelPhi calcu-
lation; (D) the surface electrostatic potential of CSF1 was viewed. All figures are displayed using Pymol (http://www.pymol. org).
FIGURE 2.  In vitro functional analyses of CSF1R variant type 
(R362). Western blot of lysates from wild type (H362) or variant 
type (R362) transfected 293T cells treated with M-CSF (20 ng/
ml) for 20 minutes. Lysates from untreated CSF1R-transfected 
cells were included as a control. Actin was used as internal 
control. Flag antibody detected the wild type (H362) and vari-
ant type (R362). Experiments were repeated three times with 
similar outcome. All blots are representative of at least four to 
six blots from three independent experiments. M-CSF, macro-
phage colony-stimulating factor.
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residues. Phosphorylation at CSF1R tyrosines activates sig-
nal transduction pathways including the ERK1/2, PI3K, and 
JNK.29,30 CSF1 was originally identified as a regulator of pro-
liferation, differentiation, and survival of macrophages and 
their bone marrow progenitors.31 However, in addition to its 
role in mononuclear phagocyte biology, CSF1 and its recep-
tor are implicated in carcinogenesis. Abnormal expression of 
CSF1 and its receptor has been documented in a wide variety 
of human carcinomas and carcinoma-derived cell lines includ-
ing tumors of epithelial origin such as carcinomas of breast, 
ovary, endometrium, prostate, and lung,32–35 and abnormal 
expression of CSF1 and CSF1R has been found to strongly 
correlate with tumor cell invasiveness and adverse clinical 
prognosis.35–37 More importantly, several studies have shown 
that overexpression of CSF1R can induce malignant trans-
formation of fibroblast and epithelial cells.38,39 Although the 
biological roles of CSF1R in lung cancer developed in never-
smokers remain to be elucidated, these studies taken together 
suggest that CSF1R might play a role in lung carcinogenesis.
To the best of our knowledge, this study is the first 
reporting that the CSF1R rs10079250G (R362) allele is asso-
ciated with an increased risk of lung cancer. To determine 
the functionality of this nonsynonymous SNP, the effect of 
rs10079250A>G on the structure and function of CSF1R 
protein was predicted through three-dimensional models 
of CSF1R that were built based on the x-ray crystal struc-
ture of the ectodomain of KIT. Homology-based model for 
CSF1R indicates that the rs10079250 A-to-G change leads to 
increased positive charge of CSF-binding region of CSF1R, 
thereby increasing the chance of interaction between CSF 
and CSF1R. In addition, compared with the rs10079250A 
allele, the rs10079250G allele exhibited an increased level of 
phosphorylated JNK, a downstream molecule of the CSF1-
CSF1R signaling pathway. Quantitative reverse transcription 
polymerase chain reaction demonstrated CSF1R expres-
sion in both tumor and corresponding normal lung tissues. 
However, there was no significant difference in the level of 
CSF1R expression among genotypes (n = 34, data not shown), 
which is possibly because CSF1R rs10079250A>G is not a 
SNP in the promoter region that may affect the expression of 
CSF1R. These findings suggest that CSF1R rs10079250A>G 
influences the binding of CSF1 to CSF1R, thus contributing to 
genetic susceptibility to lung cancer in never-smokers.
TP63 is a member of tumor suppressor TP53 gene fam-
ily. TP63 plays important roles in cell cycle arrest and apop-
tosis, and also transactivates TP53 target genes.40,41 Altered 
TP63 expression has been linked to the development and pro-
gression of various types of cancers, including lung cancer.40,41 
Recently, TP63 rs10937405 was identified and replicated as 
a susceptibility locus for lung adenocarcinoma.18,42–44 In the 
present study, TP63 rs7631358G>A was associated with an 
increased risk of lung cancer, mostly adenocarcinoma, among 
female never-smokers. The CIR1 interacts with C promoter 
binding factor 1 (CBF1, alias recombination signal binding 
protein for immunoglobulin kappa J region [RBPJ]) to func-
tion as a transcriptional corepressor.45 CBF1 plays a central 
role in Notch signaling,46 which is dysregulated in many can-
cers including lung cancer. In the present study, there was 
no difference in promoter activity between the two alleles 
of TP63 rs7631358G>A and CIR1 rs13009079T>C, which 
are located in promoter region, in luciferase assay (data not 
shown). A possible explanation is that linkage disequilibrium 
with other functional variants may be responsible for the asso-
ciation. Further studies are needed to clarify the association 
between these SNPs and the risk of lung cancer.
In this study, the association between the CSF1R 
rs10079250, TP63 rs7631358, and CIR1 rs13009079 and lung 
cancer risk was convincingly replicated across both stage of 
the study, which would largely increase confidence of the find-
ings from the genetic association study.47,48 Particularly, the 
putative function of CSF1R rs10079250A>G supports the 
plausibility of our findings. However, several limitations in 
the present study should be considered. The modest sample 
size of both cohorts does not have optimal statistical power 
for discovering and validating the association. Therefore, the 
observed p values did not reach a more stringent level of sta-
tistical significance for candidate gene studies to avoid false-
positive associations arising from multiple comparisons.47 In 
addition, although not replicated in the validation set, SNPs in 
several genes in Table 2, such as SCGB1D2, CAP1, PRDX4, 
HMGA2, and NTRK3, were significantly associated with lung 
cancer risk in the combined analysis, suggesting the possibil-
ity of the association between the SNPs and lung cancer risk. 
Notably, it has been recently reported that those genes may play 
a role in the development and progression of lung cancer.49–53 
This study did not provide direct evidence that the CSF1R, 
TP63, and CIR1 genes are involved in the development of 
lung cancer among never-smoking women, which limited our 
inquiry into the biologic mechanism of the observed associa-
tion between the SNP and lung cancer risk.
In conclusion, this study shows that three SNPs of can-
cer-related genes, particularly CSF1R rs10079250A>G, affect 
susceptibility to lung cancer in a Korean population of never-
smoking women. Larger studies are required to confirm the effect 
of these SNPs in other ethnic populations. In addition, studies 
regarding the biologic function of those genes in the development 
of lung cancer among never-smokers are needed to understand 
the role of those SNPs in determining lung cancer risk.
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